Lantern Pharma, Inc. ( (LTRN) ) has released its Q2 earnings. Here is a breakdown of the information Lantern Pharma, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lantern Pharma, Inc. is an artificial intelligence-focused biotechnology company dedicated to developing cancer therapies, leveraging its proprietary RADR® platform to streamline drug discovery and development in the oncology sector. In its latest earnings report for the quarter ending June 30, 2025, Lantern Pharma highlighted its continued focus on advancing its three clinical-stage oncology product candidates and its Antibody Drug Conjugate (ADC) program. The company reported a net loss of $4.33 million for the quarter, a slight improvement from the $4.96 million loss in the same period last year, reflecting ongoing investments in research and development. Key financial metrics showed a decrease in total assets to $17.42 million from $25.57 million at the end of 2024, primarily due to reductions in cash and marketable securities. Despite the financial losses, Lantern Pharma continues to advance its strategic initiatives, including the development of its LP-300, LP-184, and LP-284 drug candidates, as well as expanding its RADR® platform’s capabilities. Looking ahead, the company remains focused on securing additional funding to support its research and development efforts and is exploring various financing options to sustain its operations into 2026.